Lung Cancer Support
2,637 members1,245 posts

News from the FDA: the indication for a drug targeting EGFR is expanded to uncommon mutations

The FDA has expanded the indication for afatinib (Gilotrif) to include the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have uncommon EGFR alterations in L861Q, G719X, and/or S768I. This FDA approval was based on trials studying the response to afatinib in patients whose tumors had mutations in EGFR. The results help advance our understanding of the efficacy of afatinib and also highlight the importance of tumor testing of patients with lung cancer.

1 Reply

More options are good news! This is based on a small subset of patients, but response rates and duration of efficacy were're both compelling.


You may also like...